Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Featured

Autologous Transplantation for Relapsed DLBCL in the CAR-T Therapy Era

Mehdi Hamadani, MD, discusses an analysis evaluating the role of autologous transplant in relapsed DLBCL with newer therapies, specifically CAR T-cells.

Sattva S. Neelapu, MD, Talks Safety and Efficacy of ALLO-501/647 for Patients With LBCL

Dr Neelapu talks about early findings from the ALPHA study which suggest that ALLO-501 and ALLO-647 are safe and may be effective in LBCL.

CAR T-Cell Therapy Promising for Relapsed/Refractory Large B-Cell NHL

Nilanjan Ghosh, MD, reviews results from a pilot study of lisocabtagene maraleucel for the treatment of relapsed large cell lymphomas.

Pallawi Torka, MD, Discusses Outcomes of Patients With Limited-Stage Aggressive LBCL

Dr Torka talks about the outcomes of patients with limited-stage, aggressive large B-cell lymphoma and high-risk cytogenetics.

Bone Marrow Biopsy Histology Impacts Outcomes in FL, DLBCL

Sarah Rutherford, MD, discusses how postinduction bone marrow biopsy histology minimally affects radiographically-defined responses in patients with FL and DLBCL.

Sarah Rutherford, MD, discusses the results from a phase 1 study, which evaluated the combination of venetoclax and DA-EPOCH-R for aggressive B-cell lymphomas.

Dual CD19/22 Targeting CAR-T Therapy Plus Pembrolizumab Promising for DLBCL

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, discusses results from the phase 1 Alexander study, which evaluated AUTO3 plus pembrolizumab in relapsed/refractory DLBCL.

Pembrolizumab Improves PFS in Relapsed/ Refractory Classical Hodgkin Lymphoma

John Kuruvilla, MD, FRCPC, discusses the results from the phase 3 KEYNOTE‑204 trial, which compared pembrolizumab against brentuximab vedotin in relapsed/refractory classical Hodgkin lymphoma.

Triplet Combination Appears Well-Tolerated, Safe for DLBCL

Charles Herbaux, MD, MSc, discusses results from the phase 2 GATA study, which evaluated the efficacy and safety of obinutuzumab plus atezolizumab and venetoclax for relapsed/refractory DLBCL.